Innovative microbial strategies in atopic dermatitis

Atopic dermatitis (AD) is characterized by chronic and recurrent itching with a high burden of disability-adjusted life years (DALYs, a measure of overall disease burden). Traditional treatments mainly include corticosteroids, which have a good effect on controlling inflammation but adverse side eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingtai Ma, Yiting Fang, Jinxing Hu, Shiqi Li, Lilian Zeng, Siyi Chen, Zhifeng Li, Ruiling Meng, Xingfen Yang, Fenglin Zhang, Guiyuan Ji, Peihua Liao, Liang Chen, Wei Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1605434/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850073058324250624
author Jingtai Ma
Jingtai Ma
Yiting Fang
Yiting Fang
Jinxing Hu
Shiqi Li
Lilian Zeng
Siyi Chen
Zhifeng Li
Ruiling Meng
Xingfen Yang
Fenglin Zhang
Guiyuan Ji
Peihua Liao
Liang Chen
Wei Wu
Wei Wu
author_facet Jingtai Ma
Jingtai Ma
Yiting Fang
Yiting Fang
Jinxing Hu
Shiqi Li
Lilian Zeng
Siyi Chen
Zhifeng Li
Ruiling Meng
Xingfen Yang
Fenglin Zhang
Guiyuan Ji
Peihua Liao
Liang Chen
Wei Wu
Wei Wu
author_sort Jingtai Ma
collection DOAJ
description Atopic dermatitis (AD) is characterized by chronic and recurrent itching with a high burden of disability-adjusted life years (DALYs, a measure of overall disease burden). Traditional treatments mainly include corticosteroids, which have a good effect on controlling inflammation but adverse side effects. Recently, advancements in understanding the pathogenesis of AD have led to the emergence of a variety of novel therapeutic approaches, such as microbiome manipulation, offering renewed hope for more effective management of this condition. These strategies are particularly promising for mild-to-moderate AD, where dysbiosis and immune imbalance (e.g., Th2 skewing) are key drivers, though some approaches (e.g., fecal microbiota transplantation) are being explored for refractory cases. It has been shown that microbiome manipulation has the potential to improve disease states and regulates the balance of the inflammatory system in a variety of ways. Various approaches have been preclinically and clinically tested, including probiotics (and multiple co-applications), prebiotics, postbiotics, unmethylated CpG motifs, fecal microbiota transplantation, herbal fermentation technology with microorganisms and phage. In this review, we discuss these microbiome manipulation methods and emphasizes the potential of microbiome-based interventions to modulate Th1/Th2 balance with fewer side effects, ultimately leading to control of inflammation in AD. Further translational research in this field is needed to integrate when we apply this therapy and the capability for disease treatment and prevention.
format Article
id doaj-art-1199cf12081248528e4c7556fcfe1cf6
institution DOAJ
issn 1664-3224
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-1199cf12081248528e4c7556fcfe1cf62025-08-20T02:46:57ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.16054341605434Innovative microbial strategies in atopic dermatitisJingtai Ma0Jingtai Ma1Yiting Fang2Yiting Fang3Jinxing Hu4Shiqi Li5Lilian Zeng6Siyi Chen7Zhifeng Li8Ruiling Meng9Xingfen Yang10Fenglin Zhang11Guiyuan Ji12Peihua Liao13Liang Chen14Wei Wu15Wei Wu16Guangzhou Chest Hospital, Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaGuangzhou Chest Hospital, Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaGuangzhou Chest Hospital, Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaGuangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaNational Medical Products Administration (NMPA) Key Laboratory for Safety Evaluation of Cosmetics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, ChinaGuangzhou Institute of Microbiology Group Co., Ltd., Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaXinjiang Uighur Autonomous Region Center for Disease Control and Prevention, Uighur, ChinaGuangzhou Chest Hospital, Guangzhou, ChinaGuangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, ChinaZhuhai Center for Disease Control and Prevention, Zhuhai, ChinaAtopic dermatitis (AD) is characterized by chronic and recurrent itching with a high burden of disability-adjusted life years (DALYs, a measure of overall disease burden). Traditional treatments mainly include corticosteroids, which have a good effect on controlling inflammation but adverse side effects. Recently, advancements in understanding the pathogenesis of AD have led to the emergence of a variety of novel therapeutic approaches, such as microbiome manipulation, offering renewed hope for more effective management of this condition. These strategies are particularly promising for mild-to-moderate AD, where dysbiosis and immune imbalance (e.g., Th2 skewing) are key drivers, though some approaches (e.g., fecal microbiota transplantation) are being explored for refractory cases. It has been shown that microbiome manipulation has the potential to improve disease states and regulates the balance of the inflammatory system in a variety of ways. Various approaches have been preclinically and clinically tested, including probiotics (and multiple co-applications), prebiotics, postbiotics, unmethylated CpG motifs, fecal microbiota transplantation, herbal fermentation technology with microorganisms and phage. In this review, we discuss these microbiome manipulation methods and emphasizes the potential of microbiome-based interventions to modulate Th1/Th2 balance with fewer side effects, ultimately leading to control of inflammation in AD. Further translational research in this field is needed to integrate when we apply this therapy and the capability for disease treatment and prevention.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1605434/fullatopic dermatitismicrobial strategiesfecal microbiota transplantationprobioticspostbioticsprebiotics
spellingShingle Jingtai Ma
Jingtai Ma
Yiting Fang
Yiting Fang
Jinxing Hu
Shiqi Li
Lilian Zeng
Siyi Chen
Zhifeng Li
Ruiling Meng
Xingfen Yang
Fenglin Zhang
Guiyuan Ji
Peihua Liao
Liang Chen
Wei Wu
Wei Wu
Innovative microbial strategies in atopic dermatitis
Frontiers in Immunology
atopic dermatitis
microbial strategies
fecal microbiota transplantation
probiotics
postbiotics
prebiotics
title Innovative microbial strategies in atopic dermatitis
title_full Innovative microbial strategies in atopic dermatitis
title_fullStr Innovative microbial strategies in atopic dermatitis
title_full_unstemmed Innovative microbial strategies in atopic dermatitis
title_short Innovative microbial strategies in atopic dermatitis
title_sort innovative microbial strategies in atopic dermatitis
topic atopic dermatitis
microbial strategies
fecal microbiota transplantation
probiotics
postbiotics
prebiotics
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1605434/full
work_keys_str_mv AT jingtaima innovativemicrobialstrategiesinatopicdermatitis
AT jingtaima innovativemicrobialstrategiesinatopicdermatitis
AT yitingfang innovativemicrobialstrategiesinatopicdermatitis
AT yitingfang innovativemicrobialstrategiesinatopicdermatitis
AT jinxinghu innovativemicrobialstrategiesinatopicdermatitis
AT shiqili innovativemicrobialstrategiesinatopicdermatitis
AT lilianzeng innovativemicrobialstrategiesinatopicdermatitis
AT siyichen innovativemicrobialstrategiesinatopicdermatitis
AT zhifengli innovativemicrobialstrategiesinatopicdermatitis
AT ruilingmeng innovativemicrobialstrategiesinatopicdermatitis
AT xingfenyang innovativemicrobialstrategiesinatopicdermatitis
AT fenglinzhang innovativemicrobialstrategiesinatopicdermatitis
AT guiyuanji innovativemicrobialstrategiesinatopicdermatitis
AT peihualiao innovativemicrobialstrategiesinatopicdermatitis
AT liangchen innovativemicrobialstrategiesinatopicdermatitis
AT weiwu innovativemicrobialstrategiesinatopicdermatitis
AT weiwu innovativemicrobialstrategiesinatopicdermatitis